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Prognosis and risk factors for idiopathic membranous
nephropathy with nephrotic syndrome in Japan.
Background. Idiopathic membranous nephropathy (IMN)
is a representative form of refractory nephrotic syndrome in
Japan. Although IMN is thought to run a more benign course
in Japanese than in the Caucasian population, risk factors and
appropriate treatment are controversial issues.
Methods. The research group supported by a grant for “Pro-
gressive Renal Disease” from the Ministry of Health, Labor
and Welfare, Japan, carried out a national survey of patients
with IMN and nephrotic syndrome. Of 1066 nephrotic patients
with histopathologically proven IMN registered from 1975 to
1993 in 85 institutions, 949 patients were studied.
Results. The overall renal survival rates were 95.8%, 90.3%,
81.1%, and 60.5% at 5, 10, 15, and 20 years after diagnosis, re-
spectively. When clinical and histopathologic features at onset
of nephrotic syndrome were evaluated by multivariate analysis,
male gender, old age (≥60 years), high serum creatinine concen-
tration (≥1.5 mg/dL), and the development of tubulointerstitial
lesions (≥20% of the biopsy sample area) were significant pre-
dictors of progression to end-stage renal disease (ESRD). The
renal survival rate in patients on steroid therapy was signifi-
cantly higher than in patients on supportive therapy alone. Pa-
tients achieving a remission showed a significant reduction of
risk for progression.
Conclusion. IMN is a disease with a comparatively good prog-
nosis in Japan even when it is associated with nephrotic syn-
drome. Steroid therapy, which has not been recommended for
IMN in most review articles, seems to be useful at least for
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Japanese patients. In particular, a remission from heavy pro-
teinuria likely results in a favorable outcome.
Idiopathic membranous nephropathy (IMN) is the
most common form of primary glomerulonephritis caus-
ing nephrotic syndrome in adults. It is sometimes resistant
to immunosuppressive drugs resulting in end-stage renal
disease (ESRD) [1, 2], although spontaneous complete
remission also occurs in many patients [1, 3, 4]. The out-
come of IMN appears to be affected by geography and
race [1, 5]. The published data derived from the Caucasian
population revealed that ESRD develops in 20% to 40%
of patients at 10 to 15 years [1, 5, 6]. On the other hand,
IMN is thought to run a more benign course in Japanese
than in the Caucasian population [1, 5, 7, 8]. However, a
national survey of patients with IMN in Japan has never
been performed, and thus the precise outcome of IMN in
Japan is to date unknown.
In this context, the Research Group on Progressive
Renal Disease sponsored by the Ministry of Health and
Welfare of Japan launched an investigation into causes,
outcomes, and treatments of patients with nephrotic syn-
drome since 1994. The Research Group found that IMN
is the most common cause of refractory nephrotic syn-
drome in adults, which is defined as a persistence of
nephrotic syndrome resistant to treatment using corticos-
teroids and other immunosuppressive drugs for 6 months
or more. Because this condition is a risk factor for ESRD
[5, 6], the Research Group decided to survey patients
with IMN and nephrotic syndrome in Japan. We describe
the results of our retrospective investigation of prognosis
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and risk factors for renal survival in these patients. We
also discuss issues related to the treatment.
METHODS
Patients
A national survey of nephrotic patients with IMN in
Japan was performed from 1997 to 2001 by question-
naire to 85 institutions. A total of 1066 patients with his-
tologically proven IMN, in whom nephrotic syndrome
developed from 1975 to 1993, were reported by these
institutions. Nephrotic syndrome was defined by the
following criteria: (1) heavy proteinuria (urine protein
excretion >3.5 g/day), (2) hypoalbuminemia (serum al-
bumin <3.0 g/dL) or hypoproteinemia (serum total pro-
tein <6.0 g/dL), (3) edema, and (4) hypercholesterolemia
(serum total cholesterol ≥250 mg/dL). At least the first
and second criteria were necessary for the diagnosis. Of
1066 patients, 112 were later excluded because their out-
come data were incomplete or the follow-up period was
less than 6 months. Of 13 patients with high serum creati-
nine level (>3.0 mg/dL) at detection, five were excluded
because their renal function never improved and were
considered to already have ESRD at entry. Thus, 949
patients from 60 institutions were enrolled in this ret-
rospective analysis. Patients with collagen diseases, neo-
plasms and hepatitis virus infections, and those in whom
membranous nephropathy (MN) followed drug treat-
ment (i.e., gold and penicillamine) were excluded.
Clinical parameters
Blood pressure was measured at the onset of nephrotic
syndrome. Hypertension was defined as a systolic blood
pressure of higher than 140 mm Hg and a diastolic value
of higher than 90 mm Hg. Laboratory data prior to renal
biopsy were analyzed, including serum concentrations of
creatinine, urea nitrogen and total cholesterol, the num-
ber of red blood cells in urine sediment, and 24-hour
urine protein excretion and creatinine clearance. When
more than five red blood cells per high power field were
detected, patients were deemed to have hematuria.
Histopathologic parameters
Renal biopsy specimens including at least ten glomeruli
were analyzed in this study. The following five param-
eters were assessed in histopathology: events of global
sclerosis and segmental sclerosis in glomeruli, severity of
tubulointerstitial changes, occurrence of vascular lesions,
and ultrastructural stage of glomerular lesions based on
the criteria of Ehrenreich and Churg [9]. Tubulointersti-
tial changes included tubular atrophy, interstitial fibrosis,
and mononuclear cell infiltration. The extent of tubuloin-
terstitial changes was assessed semiquantitatively: grade
0, absent; grade 1, lesions occupying less than 20% of re-
nal cortex in the biopsy specimen; and grade 2, lesions
occupying 20% or more of renal cortex. Interstitial foam
cells were excluded in tubulointerstitial changes. Vascu-
lar lesions were denoted by hyaline deposits of arterioles
and intimal thickening of small arteries.
Treatment of patients
The enrolled patients were divided into three groups
based on the type of treatment: (1) the steroid group
comprised 374 patients who received corticosteroids
alone for immunosuppression; (2) the cyclophosphamide
combined group comprised 257 patients who received
corticosteroids and cyclophosphamide, and (3) the sup-
portive therapy group comprised 161 patients who
were treated with anti-platelet drugs and/or angiotensin
I-converting enzyme (ACE) inhibitors as supportive ther-
apy but never received corticosteroids or other immuno-
suppressive drugs. The remaining 157 patients received
other immunosuppressive agents such as cyclosporin, mi-
zoribine, or azathioprine. However, the number of pa-
tients in each treatment group was small. Moreover, the
protocol of treatment was incomplete, and some pa-
tients were treated with two or more immunosuppres-
sive agents. Accordingly, these patients were excluded
from the analysis of effects of treatment because we could
not examine the accurate effect of these drugs on renal
outcome.
Corticosteroids were given in the form of prednisolone
starting at 40 to 60 mg/day orally and tapered over a
period of 4 weeks or more according to the response
to therapy. Cyclophosphamide was administered orally
at 50 to 100 mg/day and stopped after 6 to 24 weeks.
Thirty-eight patients in the steroid group and two in
the cyclophosphamide combined group were given in-
travenous methylprednisolone pulses, 0.5 to 1.0 g/day for
3 consecutive days. Most patients in the steroid and cy-
clophosphamide combined groups received prednisolone
for more than 6 months. Forty-six, 16, and 37 patients in
the steroid, cyclophosphamide combined, and supportive
therapy groups, respectively, received ACE inhibitors. In
a course of treatment, antiplatelet and/or anticoagulant
drugs were also given to the majority in each group.
Criteria for clinical assessment
Clinical assessment of treatments was evaluated by
changes in proteinuria and renal function. With respect
to proteinuria, we used four categories that were usu-
ally applied to treatment effect in Japan [8]. Complete
remission (CR) was defined as absence of proteinuria
and normalized serum albumin concentration at least for
1 month. Incomplete remission (ICR) was defined as res-
olution of nephrotic syndrome but continuing protein-
uria, and was divided into two grades showing <1.0 g/day
of urine protein (ICR I) and 1.0 to 3.5 g/day (ICR II),
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respectively. No response (NR) was defined as persis-
tence of nephrotic syndrome. For renal function, three
categories were classified by serum creatinine concen-
tration: (1) normal renal function, serum creatinine
<1.5 mg/dL; (2) renal insufficiency, serum creatinine 1.5
to 2.9 mg/dL, and (3) ESRD, serum creatinine ≥3.0 mg/
dL. Renal death was interpreted as a requirement for
hemodialysis and was included in ESRD.
Data analysis
Statistical calculations were made using the Statview
software. Patient and renal survival were estimated by the
Kaplan-Meier method. The relationships of covariates to
patient and to renal survival were evaluated univariately
with the log-rank test, and multivariately with the Cox
proportional-hazards model. Blood urea nitrogen and
creatinine clearance were excluded from the multivari-
ate analysis because of correlations with serum creatinine
concentration. For comparison of treatments, analysis of
variance (ANOVA) followed by Scheffe´ test or a multiple
comparison test with adjustment of the significance level
to the inequality of Bonferroni was used to assess param-
eters of clinical features among the three groups. P < 0.05
was considered statistically significant in all analyses.
RESULTS
Clinical features at onset of nephrotic syndrome
There were 592 males and 357 females, and a male to
female ratio of 1.66:1. The patients ranged in age at on-
set of nephrotic syndrome from 15 to 87 years (average
50.5 years) and 191 (20%) patients were less than 40 years
old. The follow-up period ranged from 6 to 285 months
(average 83.3 months). Baseline proteinuria exceeding
10 g/day was noted in 177 (18.7%) patients. Microscopic
hematuria was observed in 393 (41.4%) patients. Two
hundred and two (21.3%) patients were hypertensive.
Moderate to severe renal dysfunction was noted in 90
(9.5%) patients, including eight (0.8%) patients who ex-
hibited a transient rise in serum creatinine concentra-
tion (≥3.0 mg/dL) and renal dysfunction associated with
nephrotic syndrome. Hyperlipidemia (total cholesterol
≥250 mg/dL) was diagnosed in 776 (81.8%) patients.
Prognosis
The outcome of patients with IMN at the last obser-
vation is shown in Table 1. A total of 400 (42.1%) pa-
tients entered CR and 233 (24.6%) patients had ICR
I. On the other hand, 162 (17.1%) patients had ICR II
and 154 (16.2%) patients had persistent nephrotic syn-
drome. With respect to renal function, 111 (11.7%) pa-
tients reached chronic renal insufficiency and 79 (8.3%)
progressed to ESRD including renal death. The overall
renal survival rate for patients with IMN, in which ESRD
Table 1. Outcome of patients with idiopathic membranous
nephropathy (IMN) at last observation (N = 949)
Number of patients
Clinical status (percent of total number)
Nephrotic syndrome
Complete remission 400 (42.1%)
Incomplete remission I 233 (24.6%)
Incomplete remission II 162 (17.1%)
No response 154 (16.2%)
Renal function
Normal 759 (80.0%)
Renal insufficiency 111 (11.7%)
End-stage renal disease 79 (8.3%)
Renal death 47 (5.0%)
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Fig. 1. Overall renal survival for patients with idiopathic membranous
nephropathy (IMN).
was the end point, was 95.8%, 90.3%, 81.1%, and 60.5%
at 5, 10, 15, and 20 years after onset, respectively (Fig. 1).
A total of 41 patients (4.3%) died during the obser-
vation period. Four patients died due to renal-related
causes. The nonrenal-related causes of death included
malignant tumors (N = 12), cardiovascular diseases (N =
5), stroke (N = 7), infection (N = 10), and others (N = 3).
The patient survival rate was 97.1%, 92.7%, 92.0%, and
90.4% at 5, 10, 15, and 20 years after onset, respectively.
Clinical risk factors for ESRD
The significance of each factor affecting the renal sur-
vival rate is shown in Table 2. Among the clinical parame-
ters, male gender, old age (≥50 years old), hypertension,
massive proteinuria (≥10 g/day), increased blood urea
nitrogen (≥20 mg/dL), and creatinine concentrations
(≥1.5 mg/dL) and low creatinine clearance (<70 mL/min)
were significant risk factors for ESRD by univariate anal-
ysis. However, the presence of microscopic hematuria and
serum total cholesterol concentration were not selected.
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Table 2. Clinical features at onset and univariate analysis of risk factors affecting renal survival
Number of patients
ESRD Relative
Clinical findings Variable At onset at the last P value ratio 95% CI
Gender Male 592 62 0.0010 2.57 1.46–4.53
Female 357 15 1
Age ≥70 57 10 <0.0001 16.4 6.42–42.0
60–69 184 14 0.0024 3.75 1.60–8.82
50–59 257 26 0.0006 3.69 1.75–7.79
40–49 260 17 0.076 2.01 0.93–4.58
<40 191 10 1
Urinary protein g/day ≥10 177 25 0.012 2.22 1.20–4.13
5.0–9.9 421 35 0.15 1.54 0.86–2.75
3.5–4.9 351 17 1
Microscopic hematuria (≥5/high power field) (+) 393 29 0.95 1.02 0.64–1.61
(−) 556 48 1
Hypertension (≥140/90 mm Hg) (+) 202 31 0.0009 2.16 1.37–3.41
(−) 747 46 1
Blood urea nitrogen mg/dL ≥20 207 36 <0.0001 3.05 1.95–4.77
<20 742 41 1
Serum creatinine mg/dL ≥3.0 8 3 0.033 5.77 1.79–18.6
1.5–2.9 82 20 <0.0001 3.63 2.17–6.06
<1.5 859 54 1
Creatinine clearance mL/min <30 24 8 <0.0001 9.84 4.46–21.7
30–49 79 13 0.0001 3.63 1.88–7.02
50–69 176 22 0.0036 2.29 1.31–4.01
≥70 566 28 1
Serum total cholesterol mg/dL ≥250 776 68 0.22 1.55 0.77–3.11
<250 173 9 1
ESRD is end-stage renal disease.
Table 3. Multivariate analysis of risk factors affecting renal survival
Relative
Parameters P value ratio 95% CI
Clinical findings
Gender (male) 0.0032 2.36 1.33–4.16
Age (≥60 years) 0.0023 2.25 1.33–3.78
Urinary protein (≥10 g/day) 0.49 1.20 0.71–2.02
Microscopic hematuria 0.49 1.18 0.74–1.88
Hypertension 0.078 1.55 0.95–2.52
Serum creatinine (≥1.5 mg/dL) 0.0001 2.78 1.66–4.67
Serum total cholesterol 0.31 1.45 0.71–2.94
Light microscopic findings
Global sclerosis (≥20%) 0.90 0.95 0.42–2.17
Segmental sclerosis (≥20%) 0.11 2.09 0.84–5.20
Tubulointerstitial changes (≥20%) <0.0001 4.08 2.01–8.28
Vascular lesions 0.24 1.46 0.78–2.73
In multivariate analysis (Table 3), male gender [rela-
tive risk, 2.36 (95% CI 1.33–4.16), P = 0.0032], old age
(≥60 years) [2.25 (1.33–3.78), P = 0.0023], and high serum
creatinine concentration [2.78 (1.66–4.67), P = 0.0001] re-
mained significant risk factors for progression to ESRD.
Histopathologic risk factors for ESRD
Of renal biopsy specimens obtained from 949 patients,
578 (60.9%) were available for light microscopic evalu-
ation. Forty-five patients (7.8%) were later designated
to be in ESRD. By univariate analysis, a high incidence
of global sclerosis and segmental sclerosis (present in
≥20% of total glomeruli, respectively), tubulointersti-
tial changes occupying ≥20% of the total specimen area,
and presence of vascular lesions were significant risk fac-
tors for ESRD (Table 4). By multivariate analysis, how-
ever, only tubulointerstitial changes [4.08 (2.01–8.28),
P < 0.0001] was a significant risk factor for progression
to ESRD (Table 3).
Biopsy specimens of 610 patients (64.3%) were eval-
uated by electron microscopy, and 46 (7.5%) were
subsequently designated as having ESRD. Based on
the ultrastructural stage of glomerular lesions, 154 pa-
tients were classified as stage I, 345 as stage II, 89 as
stage III, and 22 as stage IV. No significant relationship
was observed between ultrastructural stage and outcome
(Table 4).
Drug therapy, status of nephrotic syndrome, and outcome
Clinical features before treatments in the three groups
are shown in Table 5. The mean age in the support-
ive therapy group was significantly higher than that in
the cyclophosphamide combined group (P < 0.05), but
did not differ from that in the steroid group. The inci-
dence of massive proteinuria (≥10 g/day) at onset was
significantly higher in the steroid and cyclophosphamide
combined groups than in the supportive therapy group,
respectively (P < 0.001). No significant differences
existed based on gender, presence of hypertension,
serum creatinine and urea nitrogen concentrations, and
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Table 4. Histologic findings at onset and univariate analysis of risk factors affecting renal survival
Number of patients
At ESRD Relative
Histologic findings Variable onset at the last P value ratio 95% CI
Global sclerosis ≥20% 62 10 0.022 2.28 1.12–4.60
<20% 516 35 1
Segmental sclerosis ≥20% 29 6 0.0030 3.75 1.57–8.96
<20% 549 39 1
Tubulointerstitial changes ≥20% 54 17 <0.0001 6.95 3.08–15.7
1–19% 302 19 0.17 1.75 0.79–3.88
0% 222 9 1
Vascular lesions + 222 23 0.031 1.91 1.06–3.45
− 356 22 1
Ultrastructural stage I 154 11 0.74 1.28 0.28–5.91
II 345 28 0.78 1.23 0.29–5.21
III 89 5 0.70 0.72 0.14–3.74
IV 22 2 1
ESRD is end-stage renal disease.
Table 5. Clinical features at onset and outcome of nephrotic syndrome: comparison of patients with different treatments
Treatment groups
Corticosteroids Corticosteroids + Supportive
Clinical features alone cyclophosphamide therapy
Number of patients 374 257 161
Male/female 147/227 99/158 58103
Agea 51.4 ± 13.1 48.9 ± 12.7 52.3 ± 14.0b
Urinary protein (≥10 g/day) 75 (20%) 56 (21.6%) 13 (8.1%)c
Hypertension 74 (19.8%) 58 (22.6%) 40 (24.8%)
Increased blood urea nitrogen (≥20 mg/dL) 73 (19.5%) 56 (21.8%) 39 (24.2%)
Increased serum creatinine (≥1.5 mg/dL) 30 (8.0%) 28 (10.9%) 14 (8.7%)
Follow-up period yearsa 6.4 ± 4.3 7.6 ± 5.0 6.1 ± 4.4
Outcome of nephrotic syndrome
Complete remission 179 (47.9%) 106 (41.2%) 61 (37.4%)
Incomplete remission I 95 (25.4%) 65 (25.3%) 37 (23.0%)
Incomplete remission II 52 (13.9%) 47 (18.3%) 31 (19.2%)
No response 48 (12.8%) 39 (15.2%) 32 (19.9%)
aData are mean ± SD (data in parentheses are percentages of patients); bP < 0.05 vs. cyclophosphamide combined group; cP < 0.001 vs. corticosteroid alone and
cyclophosphamide combined groups.
follow-up period among the three groups. With respect to
the outcome of nephrotic syndrome, the ratio of patients
achieving CR and ICR I was higher in the steroid group
than in the supportive therapy group, but it was not sig-
nificant (P = 0.099). The renal survival rate in the steroid
group was much better than in the supportive therapy
group [0.47 (0.24–0.89), P = 0.020]. On the other hand, al-
though renal survival in the cyclophosphamide combined
group was also better than that in the supportive therapy
group [0.57 (0.31–1.07), P = 0.080], a significant differ-
ence was obtained after simultaneous adjustment for age
[0.77 (0.63–0.94), P = 0.011] (Fig. 2). There was no signif-
icant difference in renal survival between the steroid and
cyclophosphamide combined groups.
The relationship between clinical status and renal
survival rate is shown in Figure 3. Clinical status of
proteinuria correlated well with renal outcome. Patients
who attained CR during the clinical course showed a sig-
nificant reduction of risk for progression to ESRD com-
pared with patients who remained ICR II or NR [0.22
(0.063–0.74), P = 0.015 and 0.027 (0.010–0.076), P <
0.0001, respectively]. Patients in ICR I and ICR II also
had a significant decrease in relative risk compared to
patients in NR [0.036 (0.011–0.12), P < 0.0001 and 0.13
(0.058–0.286), P < 0.0001, respectively]. Although no sta-
tistical significance was observed between CR and ICR
I or between ICR I and ICR II, patients in ICR I exhib-
ited a 70% reduction of risk for ESRD compared with
patients in ICR II [0.29 (0.075–1.12), P = 0.073].
DISCUSSION
Two representative studies of IMN have been reported
from Japan, in which nephrotic patients comprised about
80% of all subjects [7, 8]. Abe et al [7] showed that the
20-year renal survival rate was over 95%. On the other
hand, the 10- and 15-year-renal survival rates reported
by Kida et al [8] were 88.4% and 80.8%, respectively. In
these previous reports, however, the number of patients
enrolled from limited hospitals was small, and the results
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Fig. 2. Renal survival rates: Comparison of patients receiving differ-
ent treatments. Patients in the corticosteroids-alone and corticosteroids
+ cyclophosphamide groups showed a significant improvement of re-
nal survival rates compared to those in the supportive therapy group,
respectively.
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Fig. 3. Comparison of renal survival rates for response to treatment.
Patients in complete remission (CR), incomplete remission I (ICR I),
and incomplete remission II (ICR II) showed a significant improvement
in renal survival rate compared to nonresponders (NR). The difference
between CR and ICR II was also significant. ∗P = 0.004; ∗∗P < 0.0001.
were therefore insufficient to draw firm conclusions. To
provide an overview of IMN in Japan with respect to clini-
cal course, effect of treatments and outcome, we enrolled
the largest number of nephrotic patients with IMN to
date. In the present study, the renal survival rate was sim-
ilar to that reported by Kida et al [8] until 15 years after
presentation, whereas the 20-year survival rate dropped
to 60%. This indicates that the long-term outcome ex-
tending over 15 years is not favorable even in Japan when
IMN is associated with nephrotic syndrome, although it
is probably still better than that in Caucasian patients
[1, 5].
In our cohort, the majority patients with IMN were
older than 40 years of age (Table 2). Accordingly, re-
duced renal survival rate after 15 years may reflect the
confounding effect of aging. To estimate the influence of
aging per se, on more than 40 years aged patients reg-
istered during the same period, we calculated the renal
survival rate of patients with nephrotic focal glomeru-
lar sclerosis (FGS) (N = 129, age at diagnosis, 54.2 ±
9.3 years) and those with nonnephrotic mesangial pro-
liferative glomerulonephritis (N = 84, age at diagnosis,
50.4 ± 7.3 years), and compared them with the renal sur-
vival rate in IMN. The results of such analysis showed a
significantly higher renal survival rate of IMN than those
of FGS and mesangial proliferative glomerulonephritis
(P < 0.001, each). Different from IMN, however, the lat-
ter two groups showed linear falls of renal survival even
after 15 years (data not shown). Therefore, the arc-shaped
renal survival curve of IMN showing unfavorable progno-
sis after 15 years is independent of aging, although aging
may be involved in long-term outcome of IMN. On the
other hand, as described in the manuscript, a total of 41
patients (4.3%) died during the observation period, and
only four patients died due to renal-related causes. Inter-
estingly, no one died of pulmonary embolism known as
a complication in IMN. This fact may be related to the
use of antiplatelet and anticoagulant drugs. Thus, the pa-
tient survival rate was more than 90% at even 20 years
after onset. As the average age of patients with IMN was
50.5 years at onset, we calculated survival rate of 50-year-
old people in Japan using abridged life tables for 2001
which was provided by the Ministry of Health, Labor and
Welfare, Japan. The data showed 98.3%, 95.8%, 92.3%,
and 86.8% at 5, 10, 15, and 20 years after 50 years of age,
respectively, and did not differ from those of patients with
IMN. Accordingly, IMN does not seem to influence the
lifetime of patients.
Accurate prediction of prognosis requires data collec-
tion from a large cohort of patients with the disease. A
number of studies have attempted to identify the risk
factors for progression to ESRD in IMN and found
the following candidates; severe nephrotic syndrome
(≥10 g/day of urine protein), hypertension, age of more
than 50 years, male gender, and renal dysfunction [3–
6, 10, 11]. Furthermore, Cattran et al [12] found that
the highest sustained 6-month period of proteinuria was
the most important factor determining long-term out-
come, using a predictive model that compared data from
Canada to those from Italy and Finland. Our study con-
firms that all of the clinical parameters mentioned above
are also univariate risk factors in Japanese patients. In
particular, male gender and increased serum creatinine
were multivariate predictors of ESRD. These results
seem to be consistent with previous studies of nephrotic
IMN [5].
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We agree with the opinion that the degree and duration
of proteinuria are valuable for prediction of prognosis
[12]. It has been reported that the clinical course for pa-
tients with nonnephrotic proteinuria is usually favorable
and that more than 10 g/day of urine protein is a risk fac-
tor for a poor outcome. However, in our study, nephrotic
patients with IMN sometimes had a poor prognosis even
if they excreted less than 10 g/day of urine protein.
Histopathologic findings obtained from renal biop-
sies are useful for forecasting the outcome of patients
with IMN. With respect to these predictors, the degrees
of tubulointerstitial changes and glomerulosclerosis, and
electron microscopic stages have been reported previ-
ously [5, 7, 11, 13–15]. In the present study, tubuloin-
terstitial changes were the only histological parameter
that was multivariate predictor of ESRD. Tubulointersti-
tial changes were observed in 60% of our patients and
had a major impact on outcome. On the other hand,
Wakai and Magil [15] demonstrated that patients with
segmental sclerosis have a significantly lower survival
compared with sclerosis-free patients. Although segmen-
tal sclerosis was a univariate predictor of ESRD, our
multivariate analysis did not confirm their finding. The re-
lationship between the ultrastructural stage of glomerular
lesions and prognosis is controversial. A better prognosis
for stages I and II was demonstrated by several groups
[11, 13, 16]. However, others showed no relationship be-
tween stage and outcome [17, 18]. To¨rnroth, Honkanen,
and Pettersson [19] reported that ultrastructural and light
microscopic changes are unreliable indicators of the dura-
tion of illness, and that the morphologic staging pertains
to one particular evolution and course of IMN. Although
we could not assess ultrastructural stages in all of our
patients, our results may support the latter opinion.
Two meta-analyses of clinical trials in IMN have re-
cently been published [20, 21]. Both reports suggested
that alkylating therapy was beneficial for achieving a CR
[20, 21]. With respect to renal function, Hogan et al [21]
demonstrated a lower probability of 5-year renal survival
in the steroid/no-therapy group than in patients receiving
alkylating agents. In this context, therapy with steroids
alone is not recommended for IMN. In Japan, however,
corticosteroids have been used as the first line drugs for
the initial treatment of nephrotic patients with IMN, and
have been considered to carry a better prognosis. Indeed,
in our current study, the 15-year renal survival rate was
excellent and exceeded 80%. Moreover, renal survival
and complete remission rates were higher in the steroid
group than in the supportive therapy group, even though
the steroid group showed severe proteinuria in compar-
ison with the supportive therapy group. These findings
are contradictory to the recent consensus [20, 21]. Our
present results were obtained by retrospective analysis,
but the data were collected from all areas of Japan with-
out any discrimination. Therefore, we believe that steroid
therapy is effective not only in inducing a remission of
nephrotic syndrome but also in preserving renal function
in Japanese patients with IMN.
When the levels of urinary protein were reduced to less
than 3.5 g/day (CR, ICR I, and ICR II), patients had a
significantly improved clinical course compared to those
with persistent nephrotic proteinuria. Among the former,
patients whose proteinuria was decreased to 1 g/day or
less (CR and ICR I) showed over 70% reduction of risk
for ESRD compared with those who persistently had
more than 1 g/day of urinary protein (ICR II). Therefore,
the assessment category of treatment used in the present
study is useful for predicting the long-term outcome of
renal function. Furthermore, these results suggested that
the goal of treatment in IMN should be to decrease pro-
teinuria to 1 g/day or less.
The results of our nationwide survey as mentioned
above allow us to make the following conclusions. IMN
is a disease with a comparatively good prognosis in Japan
even when it is associated with nephrotic syndrome. The
renal survival rate is affected by gender, age and de-
creased renal function at onset of nephrotic syndrome.
The severity of tubulointerstitial changes also provides a
useful prediction of renal outcome. Accordingly, our re-
sults confirmed several risk factors that were identified
in the previous studies in a smaller number of patients.
In addition, our results also showed that treatment with
corticosteroids is likely to be more beneficial than sup-
portive therapy in attaining a remission of the nephrotic
syndrome, which may induce a favorable clinical
course.
Our present results do not clarify whether the effect of
combination with cyclophosphamide is superior to that
of steroid-alone therapy. Meanwhile, recent studies sug-
gest that immunosuppressants, such as cyclosporin and
mycophenolate mofetil, are useful for the treatment of
IMN [22, 23]. Although we do not yet have large num-
bers of patients treated with these drugs with long-term
outcomes, clinical studies are required to clarify the ef-
fects of these drugs in IMN.
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